Lukas Hainz

Lukas Hainz

Biopharma Innovation Specialist
Lukas Hainz specializes in biopharmaceutical research and development. He unpacks research from clinical trials and explores regulatory affairs implications on the pharmaceutical industry, focusing on innovative therapies and patent development.
EU Approves GSK’s Twice-Yearly Asthma and Sinus Treatment
Biotech & Bioprocessing EU Approves GSK’s Twice-Yearly Asthma and Sinus Treatment

Managing severe, persistent respiratory conditions often feels like a relentless battle, with frequent treatments and the constant threat of debilitating flare-ups dictating the rhythm of daily life. For millions, conditions like severe asthma and chronic rhinosinusitis with nasal polyps represent

Is Kygevvi the New Hope for a Fatal Rare Disease?
Management & Regulatory Is Kygevvi the New Hope for a Fatal Rare Disease?

For families and physicians navigating the devastating course of thymidine kinase 2 deficiency (TK2d), the journey has long been one of managing inevitable decline with no approved therapeutic options available in Europe. This extremely rare and severe genetic mitochondrial disease relentlessly

Trial Launches Digital Therapy for Kids With Cancer
Research & Development Trial Launches Digital Therapy for Kids With Cancer

The journey through pediatric cancer treatment is a formidable one, marked not only by rigorous medical procedures but also by the often-unseen burdens of persistent pain, anxiety, and profound emotional distress. For countless children and their families, these psychological challenges are a daily

Gazyva Succeeds in Phase III Autoimmune Kidney Disease Trial
Biotech & Bioprocessing Gazyva Succeeds in Phase III Autoimmune Kidney Disease Trial

A groundbreaking Phase III clinical trial has revealed that the therapy Gazyva (obinutuzumab) demonstrates superior efficacy over the current standard-of-care treatment, tacrolimus, for adults grappling with primary membranous nephropathy. The MAJESTY trial’s success represents a significant

Is This the Next Breakthrough in Liver Cancer?
Research & Development Is This the Next Breakthrough in Liver Cancer?

For patients diagnosed with inoperable liver tumors, treatment options have often been limited, presenting a formidable challenge for both individuals and their medical teams. A new clinical trial, however, is offering a ray of hope by pioneering a therapy that brings the entire treatment

Can AI Revolutionize Alzheimer's Drug Discovery?
Research & Development Can AI Revolutionize Alzheimer's Drug Discovery?

For decades, the path to finding effective treatments for Alzheimer's disease has been fraught with frustratingly slow progress and a high rate of clinical failures, leaving millions of patients and their families with limited options. This long and challenging journey, however, is now reaching a

Predictive AI for Surgery – Review
Tech & Innovation Predictive AI for Surgery – Review

The decision to undergo a total hip replacement, a procedure performed hundreds of thousands of times annually, often comes with an uncertain road to recovery, yet a new wave of artificial intelligence is beginning to chart that path with unprecedented clarity. Predictive AI for surgery represents

Experts Warn of Rising Lung Cancer in Never-Smokers
Research & Development Experts Warn of Rising Lung Cancer in Never-Smokers

With the landscape of lung cancer shifting dramatically, we're seeing a concerning rise in cases among people who have never smoked. This group, once considered low-risk, now represents a significant and growing portion of diagnoses, revealing a distinct form of the disease that challenges our

20-Year Study Shows Brain Training Lowers Dementia Risk
Research & Development 20-Year Study Shows Brain Training Lowers Dementia Risk

Today, we're joined by Ivan Kairatov, a biopharma expert with deep knowledge of technological innovation in research and development. We'll be diving into the groundbreaking 20-year findings from the ACTIVE study, which suggest a specific type of cognitive training could significantly reduce the

Breakthrough Study Redefines Hypermobile EDS Genetics
Research & Development Breakthrough Study Redefines Hypermobile EDS Genetics

A profound shift in understanding the genetic roots of hypermobile Ehlers–Danlos syndrome is underway, as a landmark study dismantles the long-standing theory of a single-gene cause for this complex and often debilitating condition. For decades, the search for a solitary genetic culprit has left

Loading
Latest Articles

Subscribe to our weekly news digest.

Join now and become a part of our fast-growing community.

Invalid Email Address
Thanks for Subscribing!
We'll be sending you our best soon!
Something went wrong, please try again later